Silo Pharma Inc (NASDAQ:SILO) saw its stock surge 43.5% on Tuesday after the European Patent Office (EPO) issued a Rule 71(3) communication signaling that it intends to grant a patent for the company's stress-prevention therapy.
The EPO's communication relates to a patent application titled "Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress," which contains allowed claims covering methods to prevent stress-induced fear and depressive-like behavior using selected serotonin 4 (5-HT4) receptor agonists. The application is exclusively licensed to Silo Pharma from Columbia University.
Silo Pharma described itself as a developmental-stage biopharmaceutical company and said that, once formally granted, the patent is expected to provide protection in major European markets. To broaden the reach of that protection, the company is evaluating Unitary Patent coverage as well as key national validations - steps intended to maximize geographic scope across Europe.
The therapy described in the allowed claims focuses on pathways tied to stress resilience, rather than solely addressing symptoms after they occur. This represents a preventative treatment strategy for stress-related disorders. According to the company's stated research focus, efforts include developing new formulations and drug delivery systems for both traditional therapeutics and psychedelic treatments.
Investors reacted quickly to the EPO communication, sending the company's shares markedly higher. The announcement from the EPO is an interim procedural step that indicates intent to grant the patent, with final grant subject to completion of the patent office's formalities.
Operationally, Silo Pharma is weighing the balance between pursuing Unitary Patent protection, which can deliver single-title coverage across participating European states, and conducting individual national validations to secure rights in selected countries. The company framed these evaluations as measures to maximize the potential territorial coverage of the intellectual property once the patent is granted.
Because Silo Pharma describes itself as being at the developmental stage, the firm's programs and the asserted intellectual property remain part of an early-phase corporate profile. The company continues to focus on formulation and delivery innovations for its candidate approaches as it advances its strategy around preventative interventions for stress-related conditions.
Impacted sectors: biotechnology, pharmaceuticals, healthcare. Market participants tracking small-cap biotech equities may be particularly attentive to patent developments and intellectual property strategies that can affect commercial prospects.